Perricone C, Bartoloni E, Gerli R. Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19. Reumatologia/Rheumatology Supplements. 2021:261-264.
APA
Perricone, C., Bartoloni, E., & Gerli, R. (2021). Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19. Reumatologia/Rheumatology Supplements, 261-264.
Chicago
Perricone, Carlo, Elena Bartoloni, and Roberto Gerli. 2021. "Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19". Reumatologia/Rheumatology Supplements: 261-264.
Harvard
Perricone, C., Bartoloni, E., and Gerli, R. (2021). Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19. Reumatologia/Rheumatology Supplements, pp.261-264.
MLA
Perricone, Carlo et al. "Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19." Reumatologia/Rheumatology Supplements, 2021, pp. 261-264.
Vancouver
Perricone C, Bartoloni E, Gerli R. Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19. Reumatologia/Rheumatology Supplements. 2021:261-264.
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].
